With the wind of the pandemic at its back, the biopharma industry saw a surging tide of fundraising in 2020 that has only exponentially grown this year. But with VC dollars flowing like never before, are there some cracks showing in biopharma’s gold-tinted façade?
In the first half of 2021, total healthcare venture spending in the US has already outstripped 2020’s record-breaking totals across biotech, healthtech and beyond, putting the industry on a funding pace that could be hard to match in coming years, according to a new report from Silicon Valley Bank released Wednesday.
For the US healthcare industry writ large — which includes biotech, healthtech, diagnostics and devices — venture capital was responsible for $21.9 billion in fundraising in the first half, well past the industry’s total of $16.8 billion in 2020.
Source: Endpoints News
Confirmed Omicron cases, deaths, and admissions
France, Israel, Denmark, and Ireland have the highest cases per capita of Omicron in the world. This shows what happens with massive surges of virus spread, even ones with 60-70% less severity.
Source: Dr. Eric Topol, Scripps Institute